Twelve-month post-treatment parameters are superior in predicting hepatocellular carcinoma in patients with chronic hepatitis B.

Sang Bong AhnJun ChoiDae Won Jun Hyunwoo Oh Eileen L Yoon Hyoung-Su KimSoung Won JeongMyoung-Kuk Jang Jae-Jun ShimYong Kyun ChoHyo Young LeeSung Won HanMindie H Nguyennull null

Published in: Liver international : official journal of the International Association for the Study of the Liver (2021)

We provided a simple-to-use HCC prediction model based on presence of cirrhosis at baseline and two objective laboratory markers (AFP and platelets) measured 12 months after antiviral initiation. The model is highly accurate with excellent validation in an external cohort from a different country (AUROC 0.844) (Clinical trial number: KCT0003487).

Keyphrases

clinical trial
hepatitis b virus
high resolution
open label
study protocol
phase ii
randomized controlled trial
mass spectrometry